GT Biopharma receives Nasdaq delisting notice for low bid price

GT Biopharma, Inc.

Nasdaq notified GT Biopharma on Nov 20, 2025 that stock closed below $1 for 30 consecutive days, violating Minimum Bid Price Requirement.
Company has 180 calendar days until May 19, 2026 to regain compliance by closing at $1 for at least 10 consecutive business days.
If not cured, may qualify for additional 180-day period if it meets other listing standards and notifies Nasdaq of intent to reverse split.
Company says it will monitor bid price and assess options; no assurance compliance will be regained.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.